____________________________
Blockbusters like Losec and Nexium have not been able to provide all gastroesophageal reflux disease (GERD) patients with sufficient disease control. Time has now come for the next leap forward in the treatment of acid related diseases. Cinclus Pharma’s clinical stage drug candidate X842 takes a new approach to provide improved management of esophagitis and GERD symptoms.
Today's GERD medication has significant shortcomings
De-risked development program – phase II study in planning
X842 provides improved acid control
18.5 million
people in initial, niche target population
2,500
individuals exposed to the active metabolite of X842 in clinical trials
Team with experience from development of Losec and Nexium
Cinclus Pharma AB
Mäster Samuelsgatan 60
(C/O Regus)
111 21 Stockholm
SWEDEN
info@cincluspharma.com
Christer Ahlberg, CEO
+46 706 753 330
Kjell Andersson, CSO
Peter Unge, CMO
+46 705 763 780
Copyright © All Rights Reserved